Official Journal of
East European Branch of
CardiOncology Society
Marcel Pina Ciuffo Almeida, Thalita Barbosa González, Isabela Bispo Santos da Silva Costa, Stéphanie Itala Rizk, Bruna Morhy Borges Leal Assunção, Henrique Barbosa Ribeiro, Ludhmila Abrahão Hajjar

Otrzymano/Received: 21.11.2019 . Zaakceptowano/Accepted: 17.01.2020.

Transcatheter aortic valve replacement in a patient with renal cell carcinoma: a case report

Transcatheter aortic valve replacement in a patient with renal cell carcinoma: a case report OncoReview 2020; 1(37): 5-7. DOI: 10.24292/01.OR.120210120
STRESZCZENIE

The transcatheter aortic valve replacement (TAVR) is an important therapy for symptomatic patients with severe aortic stenosis who have an intermediate or high surgical risk. The profile of patients eligible for this therapy as first choice has changed over the last few years, with increasing indication even for patients who do not have surgical high risk. Severely ill and frail patients, elderly or patients with multiple clinical comorbidities, such as cancer might be considered for TAVR.

ABSTRACT

The transcatheter aortic valve replacement (TAVR) is an important therapy for symptomatic patients with severe aortic stenosis who have an intermediate or high surgical risk. The profile of patients eligible for this therapy as first choice has changed over the last few years, with increasing indication even for patients who do not have surgical high risk. Severely ill and frail patients, elderly or patients with multiple clinical comorbidities, such as cancer might be considered for TAVR.

POPRZEDNIE NUMERY